NDA 206073 · Boehringer Ingelheim
Glyxambi
Empagliflozin, Linagliptin · Oral · Sodium-Glucose Cotransporter 2 Inhibitor; Dipeptidyl Peptidase 4 Inhibitor
Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jan 30, 2015
Approved uses
4
Original approval plus efficacy supplements
Registered trials
544
123 Phase 3, 99 recruiting
FAERS reports
1,966
894 serious, 65 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 20, 2026.
GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease [see Clinical Studies (14.2) ] . GLYXAMBI is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease. ( 1 ) Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Has not been studied in patients with a history of pancreatitis. ( 1 ) Not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m 2 . ( 1 ) Limitations of Use GLYXAMBI is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients [see Warnings and Precautions (5.1) ] . GLYXAMBI has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using GLYXAMBI [see Warnings and Precautions (5.2) ]. GLYXAMBI is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 30...
Mechanism: GLYXAMBI GLYXAMBI contains: empagliflozin, a SGLT2 inhibitor, and linagliptin, a DPP-4 inhibitor. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Linagliptin Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 30, 2020 Supplement 21 · Efficacy LetterLabelReview
- Jul 3, 2019 Supplement 17 · Efficacy LetterLabelReview
- Dec 23, 2016 Supplement 7 · Efficacy LetterLabel
- Jan 30, 2015 Original approval · Type 4 - New Combination LabelReviewSummary Review
2 products under this application
- GLYXAMBI · EMPAGLIFLOZIN 10MG; LINAGLIPTIN 5MG · TABLET, ORAL · Prescription
- GLYXAMBI · EMPAGLIFLOZIN 25MG; LINAGLIPTIN 5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Empagliflozin" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordPivotal-lookingRecruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT06642272 · 17,200 participants (planned) · Start Oct 10, 2024 · Primary completion Dec 31, 2028
Drug: Empagliflozin 10 MG; Dapagliflozin 10 MG · For: Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 12 sites in all
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07064473 · 11,800 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 14, 2029
Drug: Vicadrostat; Empagliflozin and 1 more · For: Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases
Sites: Anniston, Alabama; Fairhope, Alabama; Guntersville, Alabama · 1,142 sites in all
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Pivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06531824 · 8,371 participants · Start Aug 30, 2024 · Primary completion Dec 31, 2026
Drug: BI 690517; Placebo matching BI 690517 and 1 more · For: Kidney Disease, Chronic
Sites: Huntsville, Alabama; Surprise, Arizona; Beverly Hills, California · 562 sites in all
- BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT01131676 · 7,064 participants · Start Jul 2010 · Primary completion Apr 2015
Drug: BI 10773 low dose; Placebo BI 10773 high dose and 4 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 615 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06424288 · 6,712 participants (planned) · Start Jun 17, 2024 · Primary completion May 22, 2028
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Mobile, Alabama; Chula Vista, California; Orange, California · 672 sites in all
- EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT03594110 · 6,609 participants · Start Jan 31, 2019 · Primary completion Jul 5, 2022
Drug: Empagliflozin; Matching placebo · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Mesa, Arizona; San Diego, California · 240 sites in all
- EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT04509674 · 6,522 participants · Start Dec 16, 2020 · Primary completion Nov 5, 2023
Drug: Empagliflozin; Placebo · For: Myocardial Infarction
Sites: Alexander City, Alabama; Birmingham, Alabama; Huntsville, Alabama · 439 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased152
- diabetic ketoacidosis149
- nausea106
- fungal infection92
- weight decreased87
- dizziness76
- vomiting71
- urinary tract infection66
- fatigue59
- drug ineffective56
- diarrhoea50
- headache49
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 209 |
| 2016 | 298 |
| 2017 | 172 |
| 2018 | 182 |
| 2019 | 211 |
| 2020 | 192 |
| 2021 | 165 |
| 2022 | 122 |
| 2023 | 142 |
| 2024 | 105 |
| 2025 | 96 |
| 2026 | 72 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Glyxambi (Empagliflozin/Linagliptin)
2024 spending
$141M
Beneficiaries
28,725
136,734 claims
Per beneficiary
$4,911
$19.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $71,473,722 |
| 2021 | $91,483,192 |
| 2022 | $114,232,906 |
| 2023 | $136,590,648 |
| 2024 | $141,061,135 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Empagliflozin in Patients with Chronic Kidney Disease.
Herrington WG, Staplin N, Wanner C, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Anker SD, Butler J, Filippatos G, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M, Anker SD, Butler J, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA, Angermann CE, Teerlink JR, et al. · Nat Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Herrington WG, Staplin N, Agrawal N, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.